EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas

Sandro Pasquali, Paola Collini, Cleofe Romagosa, Jean-Michel Coindre, Sara Pizzamiglio, Paolo Verderio, Valeria Duroni, Marta Barisella, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa und 16 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.40177 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Sandro Pasquali und 27 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazional…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Sarcoma, Soft Tissue Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Treatment of high-risk soft-tissue sarcoma (STS) of extremity or trunk wall involves neoadjuvant chemotherapy (NACT) followed by surgery. Histopathological response could estimate patient outcomes.

Objective

To characterize morphological changes in surgical specimens of patients treated with NACT with or without radiotherapy (RT) to identify histopathological features that stratify risk of recurrence and ultimately estimate the benefit from neoadjuvant treatments. Design, Setting, and Participants This was a preplanned prospective secondary analysis of the ISG-STS 1001 clinical trial, a study with both a randomized clinical trial (conducted between 2011 and 2016) and a nonrandomized patient cohort (included between 2016 and 2020) at 32 centers across Italy, Spain, France, and Poland. Participants were patients with STS randomly assigned to receive either anthracycline plus ifosfamide or histotype-tailored (also termed histology tailored) NACT. Data analyses were performed from January to June 2023.

Intervention

Participants received 3 cycles of anthracycline plus ifosfamide or histotype-tailored NACT with or without RT followed by surgery. Main Outcomes and Measures The primary outcome was disease-free survival (DFS). Histopathological features considered included the proportion of stainable tumor cells, tumor necrosis, hemorrhage, fibrohistiocytic reaction with hemosiderin, sclerosis or fibrosis, and sclerohyalinosis. The proportion of stainable tumor cells was classified according to the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group categories or as absent or present. The continuous variable of sclerohyalinosis, expressed as a percentage, was categorized based on the second tertile of its distribution (20%). Tumor necrosis, hemorrhage, fibrohistiocytic reaction with hemosiderin, sclerosis or fibrosis, which were also expressed as a percentage, were classified as absent or present.

Results

A total of 388 patients (201 in randomized cohort, 187 in nonrandomized cohort; median [IQR] age, 50 [41-60] years; 245 males [63.1%]) were evaluable for histopathological response. In the randomized cohort, after a median (IQR) follow-up of 86 (70-99) months, 115 of 201 patients (57.2%) developed a disease recurrence. The proportion of stainable tumor cells (>1%) was not associated with DFS (hazard ratio [HR], 1.47; 95% CI, 0.36-5.98; P = .59). Necrosis (>1%) was associated with shorter DFS (HR, 3.11; 95% CI, 1.36-7.14; P = .007), while sclerohyalinosis greater than 20% was associated with longer DFS (HR, 0.51; 95% CI, 0.28-0.94; P = .03). Exclusion of patients who received preoperative RT did not alter these associations. In patients randomly assigned to anthracycline plus ifosfamide (n = 98), sclerohyalinosis greater than 20% remained associated with longer DFS (HR, 0.24; 95% CI, 0.09-0.67; P = .007). These findings were confirmed when a broader cohort (n = 187) was included. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, the proportion of stainable tumor cells, currently considered as the most relevant posttreatment change, did not stratify patient risk. The findings support consideration of the presence of sclerohyalinosis (>20%) to identify patients with the best outcome after NACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapySarcomaSoft Tissue NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAnthracyclinesChemotherapy, AdjuvantDisease-Free SurvivalIfosfamideProspective Studies

Substanzen

AnthracyclinesIfosfamide

Autor:innen und Institutionen

  • Molecular Pharmacology, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori di Milano, Milano, Italy.
  • Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
  • Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Department of Pathology, Institut Bergonié, Bordeaux, France.
  • Institut National de la Santé et de la Recherche Médicale (INSERM) U1218 ACTION, Institut Bergonié, Bordeaux, France.
  • Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Zitieren

APA

Pasquali, S., Collini, P., Romagosa, C., Coindre, J. M., Pizzamiglio, S., Verderio, P., Duroni, V., Barisella, M., Palmerini, E., Quagliuolo, V., Martin Broto, J., Pousa, A. L., Grignani, G., Brunello, A., Blay, J. Y., Lugowska, I., Fontana, V., Bianchi, G., Palassini, E., …, & Gronchi, A. (2025). Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.40177

Vancouver

Pasquali S, Collini P, Romagosa C, Coindre JM, Pizzamiglio S, Verderio P, et al. Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.40177

BibTeX
@article{Pasquali2025,
  author = {Pasquali, Sandro and Collini, Paola and Romagosa, Cleofe and Coindre, Jean-Michel and Pizzamiglio, Sara and Verderio, Paolo and Duroni, Valeria and Barisella, Marta and Palmerini, Emanuela and Quagliuolo, Vittorio and Martin Broto, Javier and Pousa, Antonio Lopez and Grignani, Giovanni and Brunello, Antonella and Blay, Jean-Yves and Lugowska, Iwona and Fontana, Valeria and Bianchi, Giuseppe and Palassini, Elena and Renne, Salvatore Lorenzo and Casali, Paolo Giovanni and Miceli, Rosalba and Sbaraglia, Marta and Gambarotti, Marco and Bagué, Silvia and Dei Tos, Angelo Paolo and Stacchiotti, Silvia and Gronchi, Alessandro},
  title = {Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.40177}
}
Kostenlos starten →